Edition:
United States

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

15.16USD
23 May 2018
Change (% chg)

$-0.38 (-2.45%)
Prev Close
$15.54
Open
$15.44
Day's High
$15.64
Day's Low
$15.09
Volume
837,358
Avg. Vol
911,265
52-wk High
$17.40
52-wk Low
$7.46

Select another date:

Tue, May 8 2018

BRIEF-Amicus Therapeutics Reports Q1 Loss Per Share Of $0.28

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES

BRIEF-Amicus Therapeutics Prices Underwritten Offering Of Common Stock

* AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK

BRIEF-Amicus Therapeutics Announces Public Offering Of Common Stock

* AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat

* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study

* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUM™

BRIEF-Amicus Launches Galafold For Treatment Of Fabry Disease In Spain

* AMICUS THERAPEUTICS LAUNCHES GALAFOLD™ (MIGALASTAT) FOR TREATMENT OF FABRY DISEASE IN SPAIN Source text for Eikon: Further company coverage:

BRIEF-Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln

* AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE

BRIEF-Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat

* AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

Select another date: